Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity
Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
WATANABE, TOYOHIKO [verfasserIn] YOKOYAMA, TERUHIKO [verfasserIn] SASAKI, KATSUMI [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Melbourne, Australia: Blackwell Science Pty ; 2004 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2004 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: International journal of urology - Oxford [u.a.] : Wiley-Blackwell, 1997, 11(2004), 4, Seite 0 |
| Übergeordnetes Werk: |
volume:11 ; year:2004 ; number:4 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1442-2042.2003.00782.x |
|---|
| Katalog-ID: |
NLEJ242680712 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242680712 | ||
| 003 | DE-627 | ||
| 005 | 20210707162557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2004 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1442-2042.2003.00782.x |2 doi | |
| 035 | |a (DE-627)NLEJ242680712 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a WATANABE, TOYOHIKO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| 264 | 1 | |a Melbourne, Australia |b Blackwell Science Pty |c 2004 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. | ||
| 533 | |d 2004 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2004|||||||||| | ||
| 650 | 4 | |a capsaicin | |
| 700 | 1 | |a YOKOYAMA, TERUHIKO |e verfasserin |4 aut | |
| 700 | 1 | |a SASAKI, KATSUMI |e verfasserin |4 aut | |
| 700 | 1 | |a NOZAKI, KUNIHIRO |4 oth | |
| 700 | 1 | |a OZAWA, HIDEO |4 oth | |
| 700 | 1 | |a KUMON, HIROMI |4 oth | |
| 773 | 0 | 8 | |i In |t International journal of urology |d Oxford [u.a.] : Wiley-Blackwell, 1997 |g 11(2004), 4, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243925654 |w (DE-600)2009793-1 |x 1442-2042 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2004 |g number:4 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2004 |e 4 |h 0 | ||
| author_variant |
t w tw t y ty k s ks |
|---|---|
| matchkey_str |
article:14422042:2004----::nrvscleiieaoifrainsihergnce |
| hierarchy_sort_str |
2004 |
| publishDate |
2004 |
| allfields |
10.1111/j.1442-2042.2003.00782.x doi (DE-627)NLEJ242680712 DE-627 ger DE-627 rakwb WATANABE, TOYOHIKO verfasserin aut Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity Melbourne, Australia Blackwell Science Pty 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| capsaicin YOKOYAMA, TERUHIKO verfasserin aut SASAKI, KATSUMI verfasserin aut NOZAKI, KUNIHIRO oth OZAWA, HIDEO oth KUMON, HIROMI oth In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 11(2004), 4, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:11 year:2004 number:4 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2004 4 0 |
| spelling |
10.1111/j.1442-2042.2003.00782.x doi (DE-627)NLEJ242680712 DE-627 ger DE-627 rakwb WATANABE, TOYOHIKO verfasserin aut Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity Melbourne, Australia Blackwell Science Pty 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| capsaicin YOKOYAMA, TERUHIKO verfasserin aut SASAKI, KATSUMI verfasserin aut NOZAKI, KUNIHIRO oth OZAWA, HIDEO oth KUMON, HIROMI oth In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 11(2004), 4, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:11 year:2004 number:4 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2004 4 0 |
| allfields_unstemmed |
10.1111/j.1442-2042.2003.00782.x doi (DE-627)NLEJ242680712 DE-627 ger DE-627 rakwb WATANABE, TOYOHIKO verfasserin aut Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity Melbourne, Australia Blackwell Science Pty 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| capsaicin YOKOYAMA, TERUHIKO verfasserin aut SASAKI, KATSUMI verfasserin aut NOZAKI, KUNIHIRO oth OZAWA, HIDEO oth KUMON, HIROMI oth In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 11(2004), 4, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:11 year:2004 number:4 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2004 4 0 |
| allfieldsGer |
10.1111/j.1442-2042.2003.00782.x doi (DE-627)NLEJ242680712 DE-627 ger DE-627 rakwb WATANABE, TOYOHIKO verfasserin aut Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity Melbourne, Australia Blackwell Science Pty 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| capsaicin YOKOYAMA, TERUHIKO verfasserin aut SASAKI, KATSUMI verfasserin aut NOZAKI, KUNIHIRO oth OZAWA, HIDEO oth KUMON, HIROMI oth In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 11(2004), 4, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:11 year:2004 number:4 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2004 4 0 |
| allfieldsSound |
10.1111/j.1442-2042.2003.00782.x doi (DE-627)NLEJ242680712 DE-627 ger DE-627 rakwb WATANABE, TOYOHIKO verfasserin aut Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity Melbourne, Australia Blackwell Science Pty 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| capsaicin YOKOYAMA, TERUHIKO verfasserin aut SASAKI, KATSUMI verfasserin aut NOZAKI, KUNIHIRO oth OZAWA, HIDEO oth KUMON, HIROMI oth In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 11(2004), 4, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:11 year:2004 number:4 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2004 4 0 |
| source |
In International journal of urology 11(2004), 4, Seite 0 volume:11 year:2004 number:4 pages:0 |
| sourceStr |
In International journal of urology 11(2004), 4, Seite 0 volume:11 year:2004 number:4 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
capsaicin |
| isfreeaccess_bool |
false |
| container_title |
International journal of urology |
| authorswithroles_txt_mv |
WATANABE, TOYOHIKO @@aut@@ YOKOYAMA, TERUHIKO @@aut@@ SASAKI, KATSUMI @@aut@@ NOZAKI, KUNIHIRO @@oth@@ OZAWA, HIDEO @@oth@@ KUMON, HIROMI @@oth@@ |
| publishDateDaySort_date |
2004-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243925654 |
| id |
NLEJ242680712 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242680712</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707162557.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1442-2042.2003.00782.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242680712</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">WATANABE, TOYOHIKO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Melbourne, Australia</subfield><subfield code="b">Blackwell Science Pty</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">capsaicin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">YOKOYAMA, TERUHIKO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">SASAKI, KATSUMI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">NOZAKI, KUNIHIRO</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">OZAWA, HIDEO</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">KUMON, HIROMI</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of urology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1997</subfield><subfield code="g">11(2004), 4, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925654</subfield><subfield code="w">(DE-600)2009793-1</subfield><subfield code="x">1442-2042</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2004</subfield><subfield code="e">4</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
WATANABE, TOYOHIKO |
| spellingShingle |
WATANABE, TOYOHIKO misc capsaicin Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| authorStr |
WATANABE, TOYOHIKO |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243925654 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Melbourne, Australia |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1442-2042 |
| topic_title |
Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity capsaicin |
| publisher |
Blackwell Science Pty |
| publisherStr |
Blackwell Science Pty |
| topic |
misc capsaicin |
| topic_unstemmed |
misc capsaicin |
| topic_browse |
misc capsaicin |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k n kn h o ho h k hk |
| hierarchy_parent_title |
International journal of urology |
| hierarchy_parent_id |
NLEJ243925654 |
| hierarchy_top_title |
International journal of urology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243925654 (DE-600)2009793-1 |
| title |
Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| ctrlnum |
(DE-627)NLEJ242680712 |
| title_full |
Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| author_sort |
WATANABE, TOYOHIKO |
| journal |
International journal of urology |
| journalStr |
International journal of urology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2004 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
WATANABE, TOYOHIKO YOKOYAMA, TERUHIKO SASAKI, KATSUMI |
| container_volume |
11 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
WATANABE, TOYOHIKO |
| doi_str_mv |
10.1111/j.1442-2042.2003.00782.x |
| author2-role |
verfasserin |
| title_sort |
intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| title_auth |
Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| abstract |
Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. |
| abstractGer |
Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. |
| abstract_unstemmed |
Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
4 |
| title_short |
Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity |
| url |
http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x |
| remote_bool |
true |
| author2 |
YOKOYAMA, TERUHIKO SASAKI, KATSUMI NOZAKI, KUNIHIRO OZAWA, HIDEO KUMON, HIROMI |
| author2Str |
YOKOYAMA, TERUHIKO SASAKI, KATSUMI NOZAKI, KUNIHIRO OZAWA, HIDEO KUMON, HIROMI |
| ppnlink |
NLEJ243925654 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1111/j.1442-2042.2003.00782.x |
| up_date |
2024-07-06T02:50:03.841Z |
| _version_ |
1803796300526780416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242680712</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707162557.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1442-2042.2003.00782.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242680712</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">WATANABE, TOYOHIKO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Melbourne, Australia</subfield><subfield code="b">Blackwell Science Pty</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.Methods: The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 µM, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.Results: For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 ± 64.4 mL to 227.3 ± 112.4 mL and 133.1 ± 43.3 mL to 247.0 ± 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.Conclusion: Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">capsaicin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">YOKOYAMA, TERUHIKO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">SASAKI, KATSUMI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">NOZAKI, KUNIHIRO</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">OZAWA, HIDEO</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">KUMON, HIROMI</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of urology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1997</subfield><subfield code="g">11(2004), 4, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925654</subfield><subfield code="w">(DE-600)2009793-1</subfield><subfield code="x">1442-2042</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1442-2042.2003.00782.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2004</subfield><subfield code="e">4</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4017677 |